NYXH — Nyxoah SA Share News
0.000.00%
- €82.08m
- €52.26m
- €10.02m
Brief: Nyxoah Reports Q4 Sales Of 1.3 Mln Euros
Brief: Nyxoah Completes Milestone in Development oF DREAM U.S Pivotal Study
Brief: Nyxoah Appoints Daniel Wildman To Its Board Of Directors
Brief: Nyxoah SA Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
Brief: Nyxoah Reports Third Quarter 2022 Financial And Operating Results
Brief: Nyxoah Announces Change To Board Of Directors
Brief: Nyxoah Reports Q2 And First Half 2022 Results
Brief: Nyxoah SA Reports Q2 Revenue 935,000 EUR
Brief: Nyxoah: FDA IDE Approval To Initiate ACCESS Study Of Genio In Complete Concentric Collapse Patients
Brief: FDA Approves Genio 2.1 For Use In Dream U.S. Ide Pivotal Study
Brief: Nyxoah Q1 Net Loss Group Share Widens To EUR 6.8 Million
Brief: Nyxoah Reports First Quarter 2022 Financial And Operating Results
Brief: Nyxoah FY Operating Loss Widens To EUR 26.2 Million
RCS - Osler Diagnostics Ld - Osler Diagnostics - Board Appointments
Brief: Nyxoah SA Says Better Sleep Achieves Primary Endpoint Across All Patient Cohorts
Brief: Nyxoah Says U.S. Implants In DREAM IDE Study To Be Completed In Q1
Brief: Nyxoah Appoints New CFO
Brief: Nyxoah Says Appoints Loïc Moreau as New CFO
Brief: Nyxoah: FDA Breakthrough Device Designation Granted For Genio System